These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19999637)

  • 21. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 22. Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going?
    Joseph JN; Deaton D; Ehsan H; Bonanno MA
    J Health Life Sci Law; 2009 Jan; 2(2):73-108. PubMed ID: 19288889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

  • 24. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Proposed rule.
    Fed Regist; 1998 Jun; 63(109):31143-61. PubMed ID: 10180130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

  • 26. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.
    O'Reilly J; Dalal A
    Ann Health Law; 2003; 12(2):295-324, table of contents. PubMed ID: 12856461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 28. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
    O'Reilly J
    Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
    [No Abstract]   [Full Text] [Related]  

  • 29. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
    Gass A; Wilson J
    Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
    [No Abstract]   [Full Text] [Related]  

  • 30. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
    Bagley CE; Mitts J; Tinsley RJ
    Cornell J Law Public Policy; 2013; 23(2):337-93. PubMed ID: 25330567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Off-label' prescribing, the Physician's Desk Reference and the court.
    Spector RA; Marquez E
    J La State Med Soc; 2011; 163(5):276-80. PubMed ID: 22272550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disqualification of a clinical investigator--FDA. Final rule.
    Fed Regist; 1997 Sep; 62(172):46875-6. PubMed ID: 10173286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA Modernization Act: implications for oncology.
    Morris L
    Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
    Novak E; Allen PJ
    Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The "art" of medicine and the "smokescreen" of the randomized trial off-label use of vascular devices.
    Ansel GM; Jaff MR
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):998-1002. PubMed ID: 19021289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
    Hall RF; Sobotka E
    Food Drug Law J; 2007; 62(1):1-48. PubMed ID: 17444025
    [No Abstract]   [Full Text] [Related]  

  • 38. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
    Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 'Off-label' drug use: an FDA regulatory term, not a negative implication of its medical use.
    Meadows WA; Hollowell BD
    Int J Impot Res; 2008; 20(2):135-44. PubMed ID: 18004389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk management and intrusions on medical practice: striking a balance.
    Enzi MB; Kennedy EM
    Health Aff (Millwood); 2007; 26(3):678-80. PubMed ID: 17485743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.